Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.

About this Publication
Title
Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.
Pubmed ID
25312998 (View this publication on the PubMed website)
Publication
Cancer Epidemiol. Biomarkers Prev. 2015 Jan; Volume 24 (Issue 1): Pages 154-61
Authors
Ten Haaf K, van Rosmalen J, de Koning HJ
Affiliations
  • Department of Public Health, Erasmus MC, Rotterdam, the Netherlands. k.tenhaaf@erasmusmc.nl.
  • Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Public Health, Erasmus MC, Rotterdam, the Netherlands.
Abstract

BACKGROUND: Implementing optimal lung cancer screening programs requires knowledge of the natural history and detectability of lung cancer. This information can be derived from the results of clinical trials with the aid of microsimulation models.

METHODS: Data from the Surveillance, Epidemiology, and End Results (SEER) program and individual-level data from the National Lung Screening Trial (NLST) and the Prostate, Lung, Colon, and Ovarian Cancer Screening trial (PLCO) were used to investigate the sensitivity (by histology and stage) of CT and chest radiography (CXR) and the mean preclinical sojourn time (MPST) of lung cancer (by gender, histology, and stage). The MISCAN-Lung model was used to reproduce the lung cancer incidence by method of detection (clinically or screen-detected), gender, histology, and stage in both trials and SEER, by calibrating CT and CXR sensitivity and natural history parameters.

RESULTS: CT sensitivity ranges from 8.83% to 99.35% and CXR sensitivity from 2.51% to 97.31%, depending on histology and stage. CT sensitivity for stage IA is more than 3-fold higher compared with CXR, for all histologies. The total MPST estimates for lung cancer progressing through preclinical stages IA to IV range from 3.09 to 5.32 years for men and 3.35 to 6.01 years for women. The largest difference in total MPST between genders was estimated for adenocarcinoma.

CONCLUSIONS: We estimate longer MPSTs for lung cancer compared with previous research, suggesting a greater window of opportunity for lung cancer screening.

IMPACT: This study provides detailed insights into the natural history of lung cancer and CT screening effectiveness.

Related CDAS Studies
Related CDAS Projects